Understanding how genetic and immune factors affect bladder cancer treatment with sacituzumab and radiation.
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
This study is looking at how your genes and immune system affect how well bladder cancer patients respond to a special treatment that combines a drug called sacituzumab with radiation, so we can find out why some people do better than others and help create better treatments for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10896483 on NIH RePORTER |
What this research studies
This research investigates the genetic and immune mechanisms that influence how bladder cancer patients respond to a combination of sacituzumab, an antibody-drug conjugate, and radiation therapy. The study aims to identify why some patients benefit from this treatment while others do not, focusing on the molecular and environmental factors involved. By analyzing patient samples and treatment outcomes, the researchers hope to develop more effective therapies that improve survival and bladder preservation rates for those with muscle invasive bladder cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with muscle invasive bladder cancer who are undergoing treatment with sacituzumab and radiation.
Not a fit: Patients with non-muscle invasive bladder cancer or those who are not receiving sacituzumab or radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for bladder cancer patients, improving their chances of survival and quality of life.
How similar studies have performed: Previous research has shown promise in using antibody-drug conjugates in combination with radiation therapy for various cancers, suggesting potential for success in this approach for bladder cancer.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Chan, Timothy an-Thy — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Chan, Timothy an-Thy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.